復星醫藥(600196.SH):復星醫藥產業獲MimiVax許可
格隆匯11月13日丨復星醫藥(600196.SH)公佈,公司控股子公司上海復星醫藥產業發展有限公司(以下簡稱“復星醫藥產業”)獲得MimiVax,LLC(以下簡稱“MimiVax”)許可,在區域內(即中國大陸、香港及澳門特別行政區,下同)及領域內(即膠質母細胞瘤以及其他腫瘤和非腫瘤適應症的治療和預防,下同)使用其專有知識(know-how)和專利(但不包括製造信息及相關專利)獨家臨牀開發和商業化(包括進口、銷售,但不包括製造;下同)腫瘤免疫治療產品SurVaxM(以下簡稱“SurVaxM”或“產品”)。
截至本公告日,產品雖已於美國完成針對膠質母細胞瘤的I期安全性臨牀研究和一項針對初診膠質母細胞瘤的II期臨牀研究、並已於美國開展針對多發性骨髓瘤、神經內分泌瘤的I期臨牀研究,但仍需按試驗方案和美國食品藥品管理局(以下簡稱“美國FDA”)要求完成後續以及其他臨牀試驗後,方可向美國FDA提交新生物製品上市申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.